【レポートの概要（一部）】
1 Table of Contents
1 Table of Contents 9
1.1 List of Tables 17
1.2 List of Figures 22
2 Introduction 24
2.1 Catalyst 24
2.2 Related Reports 24
3 Disease Overview 25
3.1 Etiology and Pathophysiology 26
3.1.1 Etiology 26
3.1.2 Pathophysiology 29
3.2 Symptoms 41
4 Epidemiology 43
4.1 Risk Factors and Comorbidities 43
4.1.1 Family history of Alzheimer’s disease increases the risk by 7.5 times 44
4.1.2 APOE ε4 allele triples the risk of Alzheimer’s disease 44
4.1.3 Cardiovascular risk factors increase the risk of Alzheimer’s disease by twofold 44
4.1.4 Incidence and prevalence of Alzheimer’s disease double every five years after age 65 45
4.1.5 Diabetes doubles the risk of Alzheimer’s in men, but only marginally increases the risk in women 45
4.1.6 Women are 1.5 times more likely to develop Alzheimer’s disease than men 46
4.1.7 Mild cognitive impairment increases the risk of Alzheimer’s disease, but may be part of the causal pathway 46
4.1.8 Depression triples the risk of Alzheimer’s disease and is the most common comorbidity 47
4.1.9 Up to 70% of Alzheimer’s disease patients also suffer from anxiety 47
4.1.10 Psychosis and agitation are common comorbidities among Alzheimer’s patients 48
4.2 Global and Historical Trends 48
4.2.1 United States 49
4.2.2 5EU 49
4.2.3 Japan 50
4.2.4 China 50
4.2.5 India 50
4.3 Forecast Methodology 51
4.3.1 Sources Used 53
4.3.2 Forecast Assumptions and Methods 56
4.3.3 Sources Not Used 58
4.4 Epidemiology Forecast (2012-2022) 59
4.4.1 Prevalent Cases of Alzheimer’s Disease 59
4.4.2 Age-Specific Prevalent Cases of Alzheimer’s Disease 60
4.4.3 Sex-Specific Prevalent Cases of Alzheimer’s Disease 62
4.4.4 Age-Standardized Prevalence of Alzheimer’s Disease 63
4.5 Discussion 65
4.5.1 Conclusions Regarding Epidemiological Trends 65
4.5.2 Limitations of the Analysis 67
4.5.3 Strengths of the Analysis 67
5 Disease Management 68
5.1 Diagnosis 68
5.1.1 Probable Alzheimer’s Disease Dementia 69
5.1.2 Possible AD Dementia 70
5.1.3 Probable AD Dementia with Evidence of AD Pathophysiological Process 70
5.1.4 Possible Alzheimer’s Dementia with Evidence of the Alzheimer’s Disease Pathophysiological Process 71
5.1.5 Preclinical AD 71
5.1.6 Mild Cognitive Impairment 72
5.2 Treatment Overview 74
5.3 United States 77
5.3.1 Diagnosis 77
5.3.2 Clinical Practice 77
5.4 France 79
5.4.1 Diagnosis 79
5.4.2 Clinical Practice 79
5.5 Germany 81
5.5.1 Diagnosis 81
5.5.2 Clinical Practice 81
5.6 Italy 82
5.6.1 Diagnosis 82
5.6.2 Clinical Practice 82
5.7 Spain 84
5.7.1 Diagnosis 84
5.7.2 Clinical Practice 84
5.8 UK 85
5.8.1 Diagnosis 85
5.8.2 Clinical Practice 86
5.9 Japan 87
5.9.1 Diagnosis 87
5.9.2 Clinical Practice 88
5.10 China 90
5.10.1 Diagnosis 90
5.10.2 Clinical Practice 90
5.11 India 92
5.11.1 Diagnosis 92
5.11.2 Clinical Practice 92
6 Competitive Assessment 95
6.1 Overview 95
6.2 Strategic Competitor Assessment 95
6.3 Product Profiles – Major Brands 97
6.3.1 Aricept (donepezil hydrochloride) 97
6.3.2 Exelon (rivastigmine, rivastigmine tartrate) 103
6.3.3 Razadyne (galantamine hydrobromide) 108
6.3.4 Namenda (memantine hydrochloride) 113
7 Opportunity and Unmet Need 118
7.1 Unmet Needs Overview 118
7.1.1 Public Awareness 120
7.1.2 Specialized Institutions at Local Levels 121
7.1.3 Screening and Diagnosis 121
7.1.4 Early Intervention 122
7.1.5 Improved Clinical Trial Design 123
7.1.6 Effective Therapy 124
7.1.7 Behavioral Treatments 125
7.2 Gap Analysis 125
7.2.1 Disease Prevention 126
7.2.2 Diagnosis from Biomarkers 127
7.2.3 Behavioral Therapies 128
8 Pipeline Assessment 129
8.1 Overview 129
8.2 Clinical Trial Mapping 129
8.2.1 Clinical Trials by Country 129
8.3 Clinical Trials by Phase and Trial Status 130
8.4 Early-Stage Pipeline Assessment 133
8.5 AD Pipeline by Mechanism of Action 135
8.6 Enzymatic Processing 135
8.7 Immunization 136
8.8 Anti-Aggregation 137
8.9 “Me-Too” 137
8.10 Novel Therapeutic Approaches 138
8.11 Technology Trends Analytic Framework 139
8.12 Promising Drugs in Clinical Development 140
8.12.1 Namenda XR 141
8.12.2 Arimenda 145
8.12.3 Gammagard Liquid 10% 148
8.12.4 Solanezumab 150
8.12.5 Gantenerumab 154
8.12.6 Crenezumab 160
8.12.7 TRx0237 164
8.12.8 MK-8931 168
8.12.9 EVP-6124 172
8.12.10 Lu AE58054 176
9 Current and Future Players 180
9.1 Overview 180
9.2 Trends in Corporate Strategy 181
9.3 Company Profiles 183
9.3.1 GlaxoSmithKline 183
9.3.2 F. Hoffman-La Roche (Roche) 186
9.3.3 Pfizer 189
9.3.4 Novartis 192
9.3.5 AbbVie (Abbott Laboratories) 195
9.3.6 Lundbeck 197
9.3.7 Eli Lilly 200
9.3.8 Baxter International 204
9.3.9 EnVivo Pharmaceuticals 206
9.3.10 Adamas Pharmaceuticals 209
9.3.11 Johnson & Johnson 210
10 Market Outlook 213
10.1 Global Markets 213
10.1.1 Forecast 213
10.1.2 Global Drivers and Barriers 217
10.1.3 Alternative Scenarios 221
10.2 United States 224
10.2.1 Forecast 224
10.2.2 Key Events 228
10.2.3 Drivers and Barriers 228
10.3 France 232
10.3.1 Forecast 232
10.3.2 Key Events 236
10.3.3 Drivers and Barriers 236
10.4 Germany 240
10.4.1 Forecast 240
10.4.2 Key Events 243
10.4.3 Drivers and Barriers 243
10.5 Italy 246
10.5.1 Forecast 246
10.5.2 Key Events 249
10.5.3 Drivers and Barriers 249
10.6 Spain 251
10.6.1 Forecast 251
10.6.2 Key Events 254
10.6.3 Drivers and Barriers 254
10.7 United Kingdom 256
10.7.1 Forecast 256
10.7.2 Key Events 259
10.7.3 Drivers and Barriers 259
10.8 Japan 263
10.8.1 Forecast 263
10.8.2 Key Events 266
10.8.3 Drivers and Barriers 266
10.9 China 268
10.9.1 Forecast 268
10.9.2 Key Events 272
10.9.3 Drivers and Barriers 272
10.10 India 274
10.10.1 Forecast 274
10.10.2 Key Events 276
10.10.3 Drivers and Barriers 276
11 Appendix 279
11.1 Bibliography 279
11.2 Abbreviations 297
11.3 Methodology 304
11.4 Forecasting Methodology 304
11.4.1 Diagnosed AD patients 305
11.4.2 Percent Drug-treated Patients 306
11.4.3 Drugs Included in Each Therapeutic Class 306
11.4.4 Launch and Patent Expiry Dates 307
11.4.5 General Pricing Assumptions 308
11.4.6 Individual Drug Assumptions 310
11.4.7 Generic Erosion 316
11.4.8 Pricing of Pipeline Agents 316
11.4.9 Alternate Scenarios 317
11.5 Physicians and Specialists Included in this Study 318
11.6 About the Authors 319
11.6.1 Author 319
11.6.2 Epidemiology 319
11.6.3 Global Head of Healthcare 323
11.7 About GlobalData 324
11.8 Disclaimer 324
【レポート販売概要】
■ タイトル：アルツハイマー型認知症：世界市場（医薬品市場予測及び分析～2022）■ 英文：PharmaPoint: Alzheimer’s Disease - Global Drug Forecast and Market Analysis to 2022
■ 発行日：2013年7月31日
■ 調査会社：GlobalData
■ 商品コード：GDATA403161526
■ 調査対象地域：グローバル
- Noble Energy, Inc.：石油・ガスの開発・生産動向及びコスト分析– Q1, 2013Noble Energy, Inc. Oil & Gas Exploration and Production Operations and Cost Analysis – Q1, 2013 Summary Noble Energy, Inc. Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comprehensive information on the operational and financial performance of the company. The report is an essential source for k …
- 世界の感染症検査市場This new 950-page report from VPGMarketResearch provides analysis of the global infectious disease testing market, including emerging tests, technologies, instrumentation, sales forecasts by country, and strategic profiles of leading suppliers. The report presents: Estimated numbers of infectious disease testing laboratories, as well as test volume and sales forecasts for France, Germany, It …
- 世界のバイオシミラー市場予測The biosimilar products market is segmented into recombinant non-glycosylated proteins, recombinant glycosylated proteins, and recombinant peptides. The recombinant non-glycosylated proteins market is further segmented as insulin, granulocyte colony-stimulating factor (G-CSF), interferons, and human growth hormone; whereas the recombinant glycosylated proteins market is further broken down into er …
- Kidney Cancer：グローバル臨床試験レビューH2, 2013Kidney Cancer Global Clinical Trials Review, H2, 2013 Summary GlobalData's clinical trial report, “Kidney Cancer Global Clinical Trials Review, H2, 2013" provides data on the Kidney Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Kidney Cancer. It includes an overview of the trial numbers and their recruitment status as per the …
- 世界の手術室設備市場（2014-2018）About Operating Room Equipment An operating room is a room with a sterile environment in a healthcare facility used to perform surgical procedures. It is equipped with technically advanced equipment, which ensures patient care and enhanced operational efficiency by empowering surgeons and other healthcare professionals with greater flexibility and ease of handling. There has been an increase in th …
- 髪修復サービスの世界市場：卵胞ユニット抽出、卵胞ユニット移植、レーザー治療、卵胞ユニットストリップ手術The global hair restoration services market was valued at $8,452.5 million in 2018, and is projected to reach $12,119.4 million by 2026, growing at a CAGR of 4.6% from 2019 to 2026. Rise in bald population around the globe has been a major driving factor of the global hair restoration services market. The global hair restoration services market is segmented based on service type, gender, service p …
- 2014年戦略提言：スペインの呼吸器病診断検査市場About This ReportThis new 281-page report from Venture Planning Group presents detailed analysis of the Spanish Respiratory Diseases market, including sales forecasts and supplier shares for Adenovirus, Influenza, Legionella, Mononucleosis, Mycoplasma, Pneumonia, RSV and Tuberculosis. The report provides test volume and sales projections for Hospitals and Commercial/Private Labs. …
- カナダの心臓血管外科用機器市場見通し（～2021）Canada Cardiovascular Surgery Outlook to 2021 Summary GlobalData’s new report, "Canada Cardiovascular Surgery Outlook to 2021", provides key procedures data on the Canada Cardiovascular Surgery. The report provides procedure volumes within market segments - Coronary Artery Bypass Graft (CABG) Procedures and Isolated Valve Procedures. The data in the report is derived from dynamic market forecast m …
- 広告支出の世界市場2015-2019About Ad Spending Advertisement is a means of communication of an information about a product or service to a target audience. They are usually persuasive in nature and are mostly in a paid form. To target the audience, advertisements use every possible media that includes TV, print, Internet, radio, posters, events, visuals, and endorsements. To advertise a product or a service, a company hires a …
- がんワクチンの世界市場：予防ワクチン、治療ワクチンAbout Cancer Vaccines Cancer vaccines are biological preparations that stimulate or strengthen a person’s immune system against cancer. Cancer vaccines are usually administered intravenously. They can be used in both adults and children. The vaccines can be broadly classified into two: prophylactic and therapeutic vaccines. Prophylactic vaccines are used for the prevention of cancer, whereas thera …
- 胃炎(Gastritis)：世界の治験レビュー（2015年上半期版）Gastritis Global Clinical Trials Review, H1, 2015 Summary GlobalData's clinical trial report, “Gastritis Global Clinical Trials Review, H1, 2015" provides data on the Gastritis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Gastritis. It includes an overview of the trial numbers and their recruitment status as per the site of trial c …
- 藻類オイルの世界市場分析：グレード別（燃料、食料、飼料）、用途別（バイオ燃料、栄養補助食品、F＆B、動物飼料）、地域別（北アメリカ、ヨーロッパ、アジア太平洋、中南米･MEA）、セグメント予測 -2014-2025The global algae oil market is expected to reach USD $2.09 billion by 2025, according to a new report by Grand View Research, Inc. Rising algae oil use in biofuel applications such as biodiesel, jet fuel, aviation fuel, and gasoline, will augment growth over the next nine years. The algae oil is being employed in food & beverage applications as a natural source of omega-3, fatty acids, antioxidant …
- 航空機電動化（MEA）の世界市場展望2017-2026According to Stratistics MRC, the Global More Electric Aircraft Market is accounted for $7.10 billion in 2017 and is expected to reach $14.43 billion by 2026 growing at a CAGR of 8.2%. Optimized aircraft performance, reduced operating & maintenance cost and increase in aircraft deliveries are some of the factors propelling the growth of the market. However, a high amount of investment and longer c …
- テラヘルツ及び赤外分光の世界市場：波長（近赤外線/中赤外線/遠赤外線）、技術（ベンチトップ/ポータブル&携帯型）、用途別分析The demand for terahertz and infrared spectroscopy systems has been on the rise due to growth in the semiconductors industry, rising use of THz spectroscopy in homeland security, and burgeoning requirements of the life sciences, pharmaceutical, and chemical industries. Various regulatory authorities across industries have enforced stringent safety regulations in order to ensure that the products l …
- 装置産業向け安全システムの世界市場2015-2019About Process Safety Systems Process safety systems protect personnel and property in processing industries. They are generally used to prevent fires, explosions, and accidental release of chemicals or other hazardous materials in industries such as Oil and Gas, Chemicals and Petrochemicals, and Power. A safety system typically comprises engineered hardware and software controls. TechNavio's analy …
